| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
i
|
|
|
|
Welcome Message
|
|
v
|
|
| State-of-the Art Lecture 1 |
| Meeting Room 309 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
SOTA1 Hospital Setting: Infection control in the resistance era
|
W.-H. Seto
|
S1
|
|
| Concurrent Session 1: Hepatitis C – Discovering Genomics |
| Meeting Room 310 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS1.1 HCV genotypes in hepatitis C patients and their clinical significances
|
J. Cheng
|
S1
|
|
|
|
CS1.2 Hepatitis C pharmacogenetics
|
G. Ahlenstiel
|
S1
|
|
|
|
CS1.3 Genomic-based treatment paradigms for patients with chronic hepatitis C infection
|
A.J. Thompson
|
S1
|
|
|
|
CS1.4 Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients
|
C.-S. Hsu,
D.-S. Chen,
J.-H. Kao
|
S1-S2
|
|
| Concurrent Session 3: Invasive Fungal Infection |
| Meeting Room 311B |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS3.1 Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong
|
M. Hui
|
S2
|
|
|
|
CS3.2 Efficacy of common antifungal drugs
|
R.Y. Li
|
S2
|
|
|
|
CS3.3 Recent advances in management of cryptococcal meningitis
|
T.C. Sorrell
|
S2
|
|
|
|
CS3.4 Invasive fungal infections: Diagnosis and treatments in China
|
Y.P. Ran
|
S2-S3
|
|
| State-of-the Art Lecture 2 |
| Meeting Room 309 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
SOTA2 Highlights of the APASL Single Topic on HCV in Chiba
|
M. Omata
|
S3
|
|
| Concurrent Session 4: Hepatitis C – The Key Concepts with New Therapies |
| Meeting Room 310 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS4.1 Personalized medicine for HCV treatment
|
M.-L. Yu
|
S3-S4
|
|
|
|
CS4.2 Directly acting antivirals against HCV
|
X.G. Dou
|
S4
|
|
|
|
CS4.3 Ursodeoxycholic acid treatment for HCV patients
|
S.U. Kim
|
S4
|
|
|
|
CS4.4 Prepare for the new therapies: Current status and policy in China
|
L. Wei
|
S4
|
|
| Concurrent Session 5: Antimicrobial Resistance |
| Meeting Room 311A |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS5.1 Respiratory infections due to drug-resistant bacteria
|
D.R. Chung
|
S4
|
|
|
|
CS5.2 Antimicrobial resistance in China
|
Y.H. Xiao
|
S4-S5
|
|
| Concurrent Session 6: Vector-Borne Infection |
| Meeting Room 311B |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS6.1 Malaria: The challenge of resistance and hope of elimination
|
L.H. Tang
|
S5
|
|
|
|
CS6.2 Re-emergence of Chikungunya virus
|
Y. Poovorawan
|
S5
|
|
|
|
CS6.3 The status of antiviral development for dengue
|
S. Vasudevan
|
S5
|
|
|
|
CS6.4 Climate and dengue infection
|
Q.Y. Liu
|
S5
|
|
| State-of-the Art Lecture 3 |
| Meeting Room 309 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
SOTA3 NDM-1 as a unique marker of antibiotic resistance: when two worlds collide
|
T.R. Walsh
|
S5
|
|
| Concurrent Session 7: HBV Infection – Science for Clinicians |
| Concurrent Session 7: HBV Infection – Science for Clinicians |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS7.1 Host-immune response: Influence on antiviral efficacy in HBV-infected individuals
|
F.S. Wang
|
S6
|
|
|
|
CS7.2 Hepatitis B virus: Genotypic and virological resistance
|
P.-J. Chen
|
S6
|
|
|
|
CS7.3 cccDNA function and HBV replication
|
M. Levrero,
L. Belloni,
F. Guerrieri,
N. Pediconi
|
S6
|
|
|
|
CS7.4 Tools for the assessment of HBV resistance in clinical practice
|
V.C.S. Wong
|
S6-S7
|
|
| Concurrent Session 9: Influenza |
| Meeting Room 311B |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS9.1 Screening of influenza
|
L.C. Jennings
|
S7
|
|
|
|
CS9.2 The emergence of pandemic influenza viruses
|
G.J.D. Smith
|
S7-S8
|
|
|
|
CS9.3 Safety and effectiveness of a 2009 H1N1 vaccine in Beijing
|
|
S8
|
|
|
|
CS9.4 Antiviral treatment of H1N1: Virological response and resistance
|
P.K.S. Chan,
N. Lee,
D. Hui
|
S8
|
|
| State-of-the Art Lecture 4 |
| Meeting Room 309 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
SOTA4 Molecular genesis of drug resistant HBV
|
S.A. Locarnini
|
S8-S9
|
|
| Concurrent Session 10: Management of CHB – Factors and Trends |
| Meeting Room 310 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS10.1 Current approaches and potential strategies: Avoid and manage drug resistance
|
|
S9
|
|
|
|
CS10.2 HBsAg seroconversion as treatment endpoint: Phenomenon and reality
|
J.L. Hou
|
S9
|
|
|
|
CS10.3 A better clinical practice through quantitative HBsAg levels
|
J.Y. Park
|
S9
|
|
|
|
CS10.4 The cost effectiveness of various strategies for HBV treatment resistance
|
S.-G. Lim
|
S9
|
|
| Concurrent Session 12: Tuberculosis |
| Meeting Room 311B |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS12.1 New tools for achieving tuberculosis control
|
W.-W. Yew
|
S9
|
|
|
|
CS12.2 Recent advancements in diagnosis of TB
|
C.B.E. Chee
|
S9-S10
|
|
|
|
CS12.3 A novel rapid assay to screen for rpsL gene mutations
|
W.H. Zhang
|
S10
|
|
|
|
CS12.4 Extensively drug-resistant tuberculosis (XDR-TB) in China: Clinical characteristics and treatment outcomes
|
Q. Zhang
|
S10
|
|
| General Session 2: Decision Making in CHB Patients Management |
| Meeting Room 309 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
GS2.1 Indication to start therapy possible, optional and mandatory
|
M. Levrero
|
S11
|
|
|
|
GS2.2 Treatment endpoints for HBV
|
C.-J. Liu
|
S11
|
|
|
|
GS2.3 Management of CHB patients: Considerations for the difficult cases and special populations
|
J.D. Jia
|
S11
|
|
| Concurrent Session 14: Viral Hepatitis and Liver Cancer |
| Meeting Room 311A |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS14.1 The risk of hepatocellular carcinoma in HCV-related chronic hepatitis
|
M. Omata
|
S11
|
|
|
|
CS14.2 Risk assessment of HBV-related HCC development using liver stiffness measurement
|
S.U. Kim
|
S11-S12
|
|
|
|
CS14.3 The potential of genetically modified T cells to prevent HBV related HCC
|
A.J. Gehring
|
S12
|
|
|
|
CS14.4 Reevaluation of the carcinogenic significance of HBV integration in hepatocarcinogenesis
|
S.Z. Jiang,
Z.W. Yang,
X.J. Li,
W.J. Li,
Y.F. Wang,
J.B. Zhang,
J.L. Hou,
X.M. Chen,
H. Zhuang,
F.M. Lu
et al.
|
S12
|
|
| Concurrent Session 15: Detection and Clinical Significance of Viral Infection |
| Meeting Room 310 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS15.1 CMV in transplant recipients
|
B.-H. Tan
|
S13
|
|
|
|
CS15.2 Drug design and development against EV71 and other enteroviruses
|
T.W. Lin
|
S13
|
|
|
|
CS15.3 More and more coronaviruses after the SARS epidemic: human coronavirus HKU1 and other coronaviruses
|
P.C.Y. Woo
|
S13
|
|
| Concurrent Session 16: End Stage Liver Disease and Complications |
| Meeting Room 311A |
| |
Article Title |
Author(s) |
Pages |
|
|
|
CS16.1 Management of the complications of liver cirrhosis
|
H. You
|
S13
|
|
|
|
CS16.2 Improving survival in patients with decompensated cirrhosis
|
D.N. Amarapurkar
|
S13-S14
|
|
|
|
CS16.3 New concept in nomenclature, classification and diagnosis of liver failure
|
Y.M. Wang
|
S14
|
|
|
|
CS16.4 Treatment strategy developments of hepatitis B with liver failure
|
Z.L. Gao
|
S14
|
|
| Free Paper Presentation 1: Hepatitis C |
| Meeting Room 310 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
PL-001 USP18 stimulates HCV production in vitro: a novel mechanism for HCV resistance to interferon therapy
|
L.M. Chen,
J. Sun,
L.-T. Lin,
M.X. Ma,
C. Richardson,
A. Edwards,
J. Feld,
I. McGilvray
et al.
|
S14
|
|
|
|
OL-001 Clinico-epidemiological profile of patients with hepatitis C virus infection seen in private practice clinics in Metro Manila
|
R. Forroza,
E. Labio,
V. Banez,
J. Ong
|
S14
|
|
|
|
OL-002 Could faluvastatin affect the sustained virological response in chronic hepatitis C virus treatment?
|
M. El-Hamamsy,
M. Azmy,
G. Badr,
M. Houssein
|
S14-S15
|
|
|
|
OL-003 Genetic changes in the interferon sensitivity determining region of hepatitis C virus during the natural course of chronic hepatitis C 3a may lead to non-response to interferon therapy
|
A. Raza,
J. Asad,
N. Zaman,
H. Aziz,
S. Murtaza,
J. Irfan
et al.
|
S15
|
|
|
|
OL-004 Sequence analysis of hepatitis C virus 5′ non-coding region
|
L. Zhang,
C. Qin,
Y. An,
X. Zhang,
L. Wang
et al.
|
S15
|
|
|
|
OL-005 A higher correlation of HCV core antigen with CD4+ T cell counts in HCV/HIV coinfected patients
|
T. Shen,
X.M. Chen,
W.D. Zhang,
Y.L. Xi,
G.H. Cao,
Y.H. Zhi,
S.W. Wang,
L. Wei,
H. Zhuang,
F.M. Lu
et al.
|
S15-S16
|
|
